Skip to main content
drug protocol number
22453
drug sponsor
Bayer Saudi Arabia LLC
drug study
ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib,
drug trial site
King Faisal Specialist Hospital and Research Center (Jeddah)
drug status
Ongoing
drug phase